Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,046 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ. Brandi ML, et al. Among authors: lombardi g. J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71. doi: 10.1210/jcem.86.12.8070. J Clin Endocrinol Metab. 2001. PMID: 11739416 Review.
Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M; Italian Multicenter Autogel Study Group in Acromegaly. Ronchi CL, et al. Among authors: lombardi g. Clin Endocrinol (Oxf). 2007 Oct;67(4):512-9. doi: 10.1111/j.1365-2265.2007.02917.x. Epub 2007 Jun 7. Clin Endocrinol (Oxf). 2007. PMID: 17555511 Clinical Trial.
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G. Baldelli R, et al. Among authors: lombardi g. J Clin Endocrinol Metab. 2000 Nov;85(11):4099-103. doi: 10.1210/jcem.85.11.6948. J Clin Endocrinol Metab. 2000. PMID: 11095439 Clinical Trial.
Impact of resistance to thyroid hormone on the cardiovascular system in adults.
Pulcrano M, Palmieri EA, Mannavola D, Ciulla M, Campi I, Covelli D, Lombardi G, Biondi B, Beck-Peccoz P. Pulcrano M, et al. Among authors: lombardi g. J Clin Endocrinol Metab. 2009 Aug;94(8):2812-6. doi: 10.1210/jc.2009-0096. Epub 2009 May 12. J Clin Endocrinol Metab. 2009. PMID: 19435825 Free article.
GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC. Colao A, et al. Among authors: lombardi g. Clin Endocrinol (Oxf). 2008 Oct;69(4):613-20. doi: 10.1111/j.1365-2265.2008.03258.x. Epub 2008 Apr 10. Clin Endocrinol (Oxf). 2008. PMID: 18410555
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A. Faggiano A, et al. Among authors: lombardi g. Clin Endocrinol (Oxf). 2008 Nov;69(5):756-62. doi: 10.1111/j.1365-2265.2008.03301.x. Epub 2008 May 14. Clin Endocrinol (Oxf). 2008. PMID: 18485119 Clinical Trial.
2,046 results